CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Standard of care (SOC)Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (8)


Name (Synonyms) Correlation
drug275 Association of diltiazem and niclosamide Wiki 0.71
drug1430 Inspiratory training device Wiki 0.71
drug1046 Expiratory training device Wiki 0.71
drug3469 standard concomitant therapy Wiki 0.71
drug8 0.9% Sodium-chloride Wiki 0.71
drug1238 Heparin Wiki 0.41
drug1087 Favipiravir Wiki 0.16
drug1284 Hydroxychloroquine Wiki 0.07

Correlated MeSH Terms (8)


Name (Synonyms) Correlation
D012120 Respiration Disorders NIH 0.18
D012140 Respiratory Tract Diseases NIH 0.15
D055370 Lung Injury NIH 0.14
D014947 Wounds and Injuries NIH 0.14
D055371 Acute Lung Injury NIH 0.07
D012128 Respiratory Distress Syndrome, Adult NIH 0.06
D003141 Communicable Diseases NIH 0.06
D007239 Infection NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There are 2 clinical trials

Clinical Trials


1 Efficacy of HYdroxychloroquine and DILtiazem-nIClosamide Combination for the Treatment of Non-severe Forms of SARS-CoV2 Infection in Patients With Co-morbidities: Multicenter, Randomized, Open-labeled Controlled Trial

No optimal antiviral intervention has been yet validated to treat COVID-19 disease. Comorbidities, such as older age, obesity, diabetes, history of cardiovascular diseases are associated with poor prognosis. This study aims to evaluate the efficacy of two experimental antiviral treatments, compared to standard of care (SOC), to prevent clinical worsening, hospitalization or death at day 14 in adults with documented SARS-CoV-2 infection, asymptomatic or with symptoms lasting less than 8 days, and associated comorbidities without any severity criteria of the disease at inclusion. Participants will be randomized to receive SOC alone or SOC + hydroxychloroquine 200 mg three times a day during 10 days or SOC + association of niclosamide 2 g at J1 then 500 mg two times a day with diltiazem 60 mg three times a day during 10 days. Efficacy and tolerance of each treatments will be compared across the three treatment groups during the 28 days of follow-up.

NCT04372082 Sars-CoV2 Other: Standard of care (SOC) Drug: Hydroxychloroquine Drug: Association of diltiazem and niclosamide

Primary Outcomes

Description: Composite criteria

Measure: death

Time: At day 14

Description: clinical worsening defined by at least one of the NEWS score item > 2 (temperature >39,1°C or<35°C, cardiac rate >111 or ≤40 bpm, respiratory rate > 21 or ≤8 cycles par minute, SaO2 ≤ 93% room air (if its measure is available),need of oxygen

Measure: clinical worsening (composite criteria)

Time: At day 14

Measure: Assisted-ventilation and/or hospitalization (composite criteria)

Time: At day 14

Secondary Outcomes

Description: clinical state as reflected by NEWS scoring, the clinical state of the patient regarding respiratory state as defined by the NEWS scoring system

Measure: National Early Warning Score (NEWS)

Time: at day 3, day 8, day 14 day 28

Measure: cumulative incidence of hospitalizations

Time: at day 14

Measure: cumulative incidence of the use of oxygen therapy, non-invasive ventilation or invasive ventilation ( composite criteria)

Time: at day 14

Description: Number of patients death

Measure: Mortality

Time: at day 14 and at day 28

Measure: cumulative incidence of viral shedding on SARS-CoV-2 rt-PCR on nasopharyngeal swab;

Time: at day 3, day 8

Measure: adverse drug reactions

Time: during study, up to 28 days

2 Randomized Open-label Multicenter Parallel-group Study of Efficacy and Safety of TL-FVP-t vs. Standard of Care Therapy in Patients With Mild to Moderate Coronavirus Disease (SARS-CoV-2/COVID-19)

Randomized open-label multicenter parallel-group study of efficacy and safety of TL-FVP-t vs. standard of care therapy in patients with mild to moderate coronavirus disease (SARS-CoV-2/COVID-19)

NCT04501783 COVID-19 Drug: Favipiravir Drug: Standard of care (SOC) Drug: standard concomitant therapy

Primary Outcomes

Description: To determine the effect of TL-FVP-t vs. SOC on time to clinical improvement. The clinical improvement is defined as reduction on at least 1 score of patient clinical status according to WHO 8-category Ordinal Scale for Clinical Improvement compared to screening

Measure: Time to clinical improvement

Time: through Day 28

Description: To determine the effect of TL-FVP-t vs. SOC on time to viral clearance of SARS-CoV-2 virus as measured by PCR in oropharyngeal sampling

Measure: Time to viral clearance

Time: through Day 28

Secondary Outcomes

Description: To determine the effect of TL-FVP-t vs. SOC on proportion of subjects (%) with clinical improvement according to WHO 8-category Ordinal Scale for Clinical Improvement

Measure: Rate of clinical improvement at separate time points

Time: Day 7

Description: To determine the effect of TL-FVP-t vs. SOC on a proportion of subjects (%) with viral clearance of SARS-CoV-2 virus as measured by PCR in oropharyngeal sampling at separate time points

Measure: Rate of viral clearance at separate time points

Time: Days 5 and 7

Description: To determine the effect of TL-FVP-t vs. SOC on time to body temperature normalization determined as body temperature < 37°C without antipyretics for at least 48 hours.

Measure: Time to body temperature normalization

Time: through Day 28

Description: To determine the effect of TL-FVP-t vs. SOC on a proportion of subjects (%) with resolution of lung changes on CT

Measure: Rate of resolution of lung changes on CT

Time: Day 14

Description: To determine the effect of TL-FVP-t vs. SOC on a proportion of subjects (%) with ADR and serious ADR

Measure: Rate of adverse drug reactions (ADR) and serious ADR

Time: through Day 28

Description: To determine the effect of TL-FVP-t vs. SOC on a proportion of subjects (%) with severe ADR

Measure: Rate of severe ADR

Time: through Day 28

Description: To determine the effect of TL-FVP-t vs. SOC on a proportion of subjects (%) discontinued therapy due ADR

Measure: Rate therapy termination due to ADR

Time: through Day 28


No related HPO nodes (Using clinical trials)